A study conducted by Hatanaka et al. [145] ascertained that a high score of the pre-treatment serum modified ALB–BIL grade combined with pre-treatment serum AFP level independently predicted worse OS and PFS in HCC patients receiving molecular targeted therapy with atezolizumab and bevacizumab. The gene discussed is AFP; the disease is hepatocellular carcinoma.